Navigation Links
Investigational eye treatment: Corneal collagen crosslinking research study
Date:9/20/2010

Teaneck, NJ The Cornea and Laser Eye Institute, with Principal Investigator, Peter S. Hersh M.D., is conducting a research study to study the safety and effectiveness of corneal collagen crosslinking (CXL) using Riboflavin/Dextran and Hypotonic Riboflavin in patients with progressive keratoconus and corneal ectasia.

Keratoconus is a disease of the cornea, the clear front lens of the eye (like the crystal on a watch), that occurs in the overall population at a rate of about one in 2000. It usually begins in the teens and 20's and can worsen over time. It is often discovered when vision cannot be properly corrected with glasses. Keratoconus results in thinning of the corneal tissues. Consequently, the cornea bulges out of its smooth, clear, dome-like structure, and assumes a more conical and irregular configuration. Because of this change in shape, the cornea loses its ability to form a clear image in the eye and the patient's vision can decrease drastically. Treatments include specialty keratoconus contact lenses and corneal inlays. However, the keratoconus cornea can continue to bulge over time and some keratoconus patients ultimately may require corneal transplantation to regain vision.

Corneal collagen crosslinking (CXL) using ultraviolet light combined with riboflavin (Vitamin B2) is an investigational procedure designed to strengthen the cornea and decrease the progression of keratoconus. CXL is an investigational procedure and is not approved for use in the United States. However, here at the CLEI Center for Keratoconus, we are participating in a research study of CXL. The goal of the study is to assess the safety and efficacy of crosslinking for the treatment of keratoconus as well as corneal ectasia after LASIK. If successful, CXL may decrease progression of keratoconus and maintain the patient's vision over time.

During the crosslinking procedure, anesthesia drops are administered. The surface epithelial cells of the cornea are then removed and riboflavin drops are administered for 30 minutes. The riboflavin acts both to enhance the crosslinking effect and to protect the rest of the eye from the UV exposure.

The patient then looks at a UV emitting light for 30 minutes. At the conclusion of the procedure, a soft contact lens bandage is applied. The contact lens is left in place to improve healing for approximately 5 days and is then removed. Antibiotic and anti-inflammatory drops are used for two weeks afterwards.


'/>"/>

Contact: Stacey Lazar
slazar@vision-institute.com
201-883-0505
The Cornea and Laser Eye Institute, P.A.
Source:Eurekalert

Related medicine news :

1. New investigational compound targets pancreatic cancer cells
2. Pivotal data for the investigational treatment PSD502 for primary premature ejaculation
3. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
4. Study finds new key to corneal transplant success
5. Khanna Institute to Provide Intacs Corneal Implants in Beverly Hills
6. Corneal Transplant Not Hurt by Long Preservation Time
7. Collagen manufactured from transgenic tobacco plants at Hebrew University
8. Hard to Treat Diseases (HTDS) Collagenna Skin Care Business Model and Chilean Update
9. Drug to treat alcoholism goal of UH professors research
10. Mayo-led researchers discover genetic variants modifying breast cancer risk
11. Rutgers researchers discover how HIV resists AZT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys during ... wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy and ... exchange for generous donations, customers will receive a gift in return. Anyone who ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic ... redesigned website, which launched October 17, 2016, features comprehensive information regarding a wide ... layout. Visitors and patients can discover the latest clinical dermatology treatments for medical ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Campaign Winner in the Folio: Marketing Awards competition. Live From won in the ... in pioneering, inventive, and ultimately successful projects undertaken by the media industry’s most ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
(Date:12/7/2016)... ... , ... “Walking With God: Inspirational Lessons from My Life's Journey”: a ... aware of God's direction in their lives. “Walking With God: Inspirational Lessons from My ... church leader. , Sanford says, “I enjoy sharing the true stories in ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- Today, Stock-Callers.com presents four Biotech equities for ... Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ), ProNAi Therapeutics ... AVXS ). From its peak in July 2015, ... a level equal to what it saw at the start ... the year, it has still out-performed other market sectors, beating ...
(Date:12/7/2016)...  Lannett Company, Inc. (NYSE: LCI ) today announced ... Prescription for Success Healthcare Conference on December 14, 2016 at 9:20 ... York City . In addition, the company will ... 4 th Annual Boston Healthcare Conference taking place on December ... ...
(Date:12/6/2016)... Dec. 6, 2016  Licenders is bringing their 100% all-natural lice ... in Park Slope at 203 13 th Street was specifically ... clientele. "Our goal is to ease parents, stress ... designed to get children right back to class without skipping a ... natural and safe for the whole family," Licenders President Adie ...
Breaking Medicine Technology: